



This open access document is published as a preprint in the Beilstein Archives with doi: 10.3762/bxiv.2019.148.v1 and is considered to be an early communication for feedback before peer review. Before citing this document, please check if a final, peer-reviewed version has been published in the Beilstein Journal of Organic Chemistry.

This document is not formatted, has not undergone copyediting or typesetting, and may contain errors, unsubstantiated scientific claims or preliminary data.

Preprint Title Syntheses of xanthone derivatives and their bioactivity investigation

Authors Beidou Zhou, Zhimin Weng, Yugui Tong, Zetong Ma, Rongrong Wei, Jiali Li and Zihan Yu

Publication Date 27 Nov 2019

Article Type Full Research Paper

Supporting Information File 1 supporting information-bdz.doc; 1.6 MB

ORCID® iDs Beidou Zhou - <https://orcid.org/0000-0001-8939-2386>

Syntheses of xanthone derivatives and their bioactivity investigation

Bei-Dou Zhou^{1*}, Zhi-Min Weng¹, Yu-Gui Tong², Ze-Tong Ma¹, Rong-Rong Wei¹, Jia-Li Li¹, Zi-Han Yu¹

¹ School of pharmacy and medical technology, Putian university, Putian 351100, China; Key laboratory of pharmaceutical analysis and laboratory medicine (Putian university), Fujian province university, Putian 351100, China

² Putian Entry-Exit Inspection and Quarantine Bureau, Putian 351100, China

*Correspondence author. Email: Beidouzhou@ptu.edu.cn

Received:

Accepted:

Published:

Abstract

Seventeen substituted 1-hydroxy-3-methylxanthenes were synthesized in one step. The yields ranged from 33 to 76%. Then, the antitumor, antioxidant, anti-tyrosinase, anti-pancreatic lipase, and antifungal activities of compounds **1–17** were evaluated. Compounds **10–12** and **14** inhibited tyrosinase and pancreatic lipase activity to a certain extent, respectively. Compound **16** exhibited obvious cytotoxicity against fifteen cancer cells, moderate antioxidant activity, and moderate activity against *Candida albicans*. In particular, compound **16** exhibited strong inhibitory activity against A-549 and A549/Taxol cells. Compound **17** exhibited moderate cytotoxicity against hepatoma SMMC-7721 cells. These results demonstrated that compounds **10–12**, **14**, and **16–17** are promising leads for further structural modification.

Keywords: xanthone; antitumor activity; anti-tyrosinase; antioxidation, pancreatic lipase; antifungal activity

1. Introduction

Many natural xanthenes are found in some plants and microorganisms, such as mangosteen. This class of compound exhibits various biological activities and the compounds are important organic synthesis intermediates. Some natural xanthenes have been isolated from the root, fruit, and twigs of *Cratoxylum cochinchinense*, including cochinchinones E–G, 7-geranyloxy-1,3-dihydroxyxanthone, and celebixanthone [1]. 7-Geranyloxy-1,3-dihydroxyxanthone and celebixanthone both strongly inhibited MCF-7, HeLa, and HT-29 cells with IC₅₀ values of 0.32–0.40 and 0.2 µg/mL, respectively [1]. Three prenylated xanthenes, jacareubin, 1,3,5-trihydroxy-2-(3,3-dimethylallyl)-xanthone, and 1,3,5,6-tetrahydroxy-2-(3,3-dimethylallyl)-xanthone, were isolated from the tropical tree *Calophyllum brasiliensis*. They inhibited the mycelial growth of *Postia placenta* at 0.25 mg/ml [2]. Other natural xanthenes have been isolated from *Garcinia mangostana* L. and been shown to have cancer chemopreventive and antioxidant action, including 8-hydroxycudraxanthone G, mangostingone, garcinones D–E, α-mangostin, and γ-mangostin. Moreover, α-mangostin inhibited 7,12-dimethylbenz[α]anthracene-induced preneoplastic lesions in a mouse mammary organ culture assay with an IC₅₀ of 1.0 µg/mL (2.44 µM) [3].

Some substituted 1,3-dihydroxyxanthenes have been synthesized and shown to exhibit a variety of biological activities. 7-Chloro-1,3-dihydroxyxanthone exhibited obvious cytotoxicity against a hepatoma cell line (SMMC-7721) and a cervical carcinoma cell line (HeLa) with IC₅₀ values of 6.14 and 13.73 µM, respectively; 1,3,5,6-tetrahydroxyxanthone exhibited strong cytotoxicity

against a T-cell leukemia cell line (MT-4) with an IC_{50} of 9.05 μ M and obvious antioxidant activity with 47.1% inhibition [4]. Both 1,3-dihydroxy-6-trifluoromethylxanthone and 7-(2,4-difluorophenyl)-1,3-dihydroxyxanthone exhibited obvious cytotoxicity against some tumor cell lines, including lung cancer A-549 cells, Taxol-resistant lung cancer A549 cells, and hepatoma SMMC-7721 cells, as well as showing anti-tyrosinase activity with inhibition of 11.3 and 19.3%, respectively [4-5].

The activity is determined by the different substituents and their positions on the xanthone core. The hydroxyl group at the C3 position of 1,3-dihydroxyxanthone is replaced by a methyl group to obtain 1-hydroxy-3-methylxanthone. To further study the structure–activity relationship of xanthenes, seventeen substituted 1-hydroxy-3-methylxanthenes were designed and synthesized, then their antitumor, antioxidant, anti-tyrosinase, anti-pancreatic lipase, and antifungal activities were assessed.

2. Results and discussion


2.1. Synthesis

Compounds **1–17** were synthesized in Eaton's reagent in one step according to a previously reported method (Schemes 1 and 2) [4]. Owing to the formation of an intermolecular hydrogen bond, a substituted salicylic acid was substituted at the C4 position of 3,5-dihydroxytoluene, followed by dihydroxy dehydration and cyclization to give a substituted 3-methyl-1-hydroxyxanthone. These xanthenes contain a hydroxyl group with a chemical shift of approximately 12.0 ppm, indicating that the hydroxyl group is close to the electron-withdrawing carbonyl group. Therefore, it must be at the C1 position on the xanthone, which strongly proves the above selective substitution.


Theoretically, the product of the reaction of 3,5-diiodosalicylic acid with 3,5-dihydroxytoluene is 1-hydroxy-5,7-diiodo-3-methylxanthone. However, the two iodines in this predicted product were replaced by the hydrogen of methanesulfonic acid to give 1-hydroxy-3-methylxanthone (**12**). Theoretically, 3-hydroxysalicylic acid reacts with 3,5-dihydroxytoluene to give 1,5-dihydroxy-3-methylxanthone. However, the hydrogen of the hydroxyl group at the C5 position of this product was substituted by the methyl group of methanesulfonic acid, providing 1-hydroxy-5-methoxy-3-methylxanthone (**13**) as the product. 5-Hydroxysalicylic acid reacted with 3,5-dihydroxytoluene to give 1-hydroxy-7-methoxy-3-methylxanthone (**14**) for the same reason. 6-Hydroxysalicylic acid reacted with 3,5-dihydroxytoluene to give 1,8-dihydroxy-3-methylxanthone (**15**). Because the two phenolic hydroxyl groups of compound **15** and the adjacent carbonyl formed intramolecular hydrogen bonds, these two hydroxyl groups were not converted to methoxy groups.

2,3,4-Trihydroxybenzoic acid reacted with 3,5-dihydroxytoluene to give 1,5,6-trihydroxy-3-methylxanthone (**16**) and 1,6-dihydroxy-5-methoxy-3-methylxanthone (**17**). As with the syntheses of compounds **13–14**, one of the hydroxyl groups in compound **16** was methylated to give compound **17**. The hydroxyl hydrogens at the C2, C5, and C6 positions of compound **16** exhibited chemical shifts of 12.83, 8.73, and 9.25 ppm, respectively. The chemical shifts of the two hydroxyl hydrogens of compound **17** were 12.58 and 10.61 ppm, respectively. In addition to the obvious hydroxyl group at the C2 position, the high chemical shift of 10.61 ppm for a hydroxyl hydrogen indicates that the hydroxyl group is *para* to the carbonyl group in compound **17**. The methoxy group and the hydrogen at C7 did not produce a cross peak in the ROESY

spectrum for compound **17**. These NMR results indicate that the hydroxyl group at the C5 position of compound **17** was methylated.



Scheme 1. Synthetic route of compounds **1-15**



Scheme 2. Synthetic route of compounds **16-17**

2.2 Biological activity

2.2.1 Antitumor activity

The *in vitro* cytotoxic activity of compounds **1-15** and **17** was evaluated against five human cancer cell lines, including a promyelocytic leukemia cell line (HL-60), a lung cancer cell line (A-549), a hepatocarcinoma cell line (SMMC-7721), a breast cancer cell line (MCF-7), and a colon cancer cell line (SW480). The *in vitro* cytotoxic activity of compound **16** was evaluated against sixteen human cancer cell lines and two normal human cell lines, including hepatoma cell lines (SMMC-7721, HepG-2, Huh-7, SK-HEP-1, MHCC97H, and PLC/PRF/5), a normal liver cell line (L02), lung cancer cell lines (A-549, NCI-H460, NCI-H520, and SPC-A-1), a Taxol-resistant lung cancer cell line (A549/Taxol), a normal lung epithelial cell line (BEAS-2B), a leukemia cell line (HL-60), breast cancer cell lines (MCF-7 and MDA-MB-231), a colon cancer cell line (SW480), and a cervical carcinoma cell line (HeLa). Two anticancer drugs, cisplatin and Taxol, were co-assayed as the positive control. The inhibition of the compound was greater than 50% and the IC₅₀ value (concentration required to inhibit tumor cell proliferation by 50%) relative to the corresponding tumor cell line was determined subsequently. These results are reported in Tables 1–3.

Compounds **1-15** inhibited the five tested cancer cells by less than 50%. Among them, compound **5** exhibited the strongest cytotoxicity against SMMC-7721 cells with 46.4% inhibition. Compound **16** exhibited moderate-to-strong cytotoxicity against 15 of the 16 tested cancer cell lines, including SMMC-7721, HepG-2, Huh-7, SK-HEP-1, PLC/PRF/5, A-549, NCI-H460, NCI-H520, SPC-A-1, A549/Taxol, HL-60, MCF-7, MDA-MB-231, SW480, and HeLa.

Compound **16** inhibited the above cell lines by 52 to 89%, with IC₅₀ values ranging from 5.90 to 37.18 μM. In particular, compound **16** exhibited strong cytotoxicity against A-549 and A549/Taxol cells with IC₅₀ values of 9.37 and 6.41 μM (<10 μM), respectively. The IC₅₀ values for cisplatin against A-549 and A549/Taxol cell lines were 15.59 and 11.77 μM, respectively. Thus, compound **16** was more cytotoxic against the two cancer cells than cisplatin. Compound **16** inhibited L02 and BEAS-2B cells by 75% and 54% with IC₅₀ values of 19.63 and 31.15 μM, respectively. Compound **16** exhibited moderate cytotoxicity against both L02 and BEAS-2B cells. Thus, it could be considered for targeted administration to reduce its cytotoxicity against normal liver and lung cells. For the above 5 tumor cells, compound **17** exhibited moderate cytotoxicity only against SMMC-7721 cells with 74.95% inhibition and an IC₅₀ value of 13.93 μM. The IC₅₀ value of compound **16** against SMMC-7721 cells was 14.22 μM. Therefore, compounds **16** and **17** exhibited comparable inhibitory activities against SMMC-7721 cells. The antitumor activity of compound **16** was greatly reduced by methyl etherification of the hydroxyl group at the C5 position.

Among the 17 3-methyl-1-hydroxyxanthenes prepared in this work, only compound **16** contains two adjacent phenolic hydroxyl groups at the C5 and C6 positions. Therefore, this structural motif contributes to its superior and broad-spectrum antitumor activity.

Table 1. IC₅₀ values of compound **16-17** against corresponding cancer cell lines

Compd	IC ₅₀ (μM)				
	HL-60	A-549	SMMC-7721	MCF-7	SW480
16	14.98 ± 0.15	9.37 ± 0.52	14.22 ± 0.65	21.81 ± 1.61	17.20 ± 0.82
17	-	-	13.93 ± 0.69	-	-
Cisplatin	3.22 ± 0.10	15.59 ± 0.26	10.66 ± 0.26	15.29 ± 1.11	15.45 ± 0.32
Taxol	<0.008	<0.008	0.81 ± 0.075	<0.008	<0.008

Note: “-” means not being determined.

Table 2. IC₅₀ values of compound **16** against cancer and normal liver cell lines

Compd	IC ₅₀ (μM)					
	HepG2	Huh-7	SK-HEP-1	PLC/PRF/5	HeLa	L02
16	12.57 ± 0.11	21.39 ± 0.66	28.83 ± 1.82	34.16 ± 3.02	18.76 ± 0.17	19.63 ± 0.43
Cisplatin	2.80 ± 0.10	13.27 ± 0.38	8.60 ± 0.54	11.13 ± 0.13	4.97 ± 0.20	8.84 ± 0.20
Taxol	<0.008	0.080 ± 0.005	<0.008	<0.008	<0.008	<0.008

Table 3. IC₅₀ values of compound **16** against cancer and normal lung epithelial cell lines

Compd	IC ₅₀ (μM)					
	NCI-H460	NCI-H520	MDA-MB-231	SPC-A-1	A549/Taxol	BEAS-2B
16	30.44 ± 1.89	15.09 ± 0.56	28.84 ± 0.28	14.12 ± 0.45	6.41 ± 0.51	31.15 ± 2.61
Cisplatin	17.35 ± 0.36	14.41 ± 0.89	26.68 ± 1.38	11.86 ± 0.66	11.77 ± 0.92	> 40
Taxol	<0.008	<0.008	<0.008	<0.008	0.40 ± 0.03	> 5

2.2.2 DPPH radical scavenging activity

The antioxidant activity assay results are presented in Table 4. Compound **16** containing two

ortho-hydroxyl groups exhibited the strongest antioxidant activity [4]. Therefore, only compound **16** was detected. Trolox was used as a positive control. Compound **16**, named 1,5,6-trihydroxy-3-methylxanthone, exhibited stronger antioxidant activity than the positive control with inhibition of approximately 62.3% versus approximately 47.1% for 1,3,5,6-tetrahydroxyxanthone [4]. Therefore, substituting the hydroxyl group at the C3 position of 1,3,5,6-tetrahydroxyxanthone for a methyl group greatly improved the antioxidant activity.

Table 4. Screening result of DPPH radical scavenging activity of compound **16**

Compd	Conc (μM)	Antioxidant (%)	Compd	Conc (μM)	Antioxidant (%)
Trolox	25	71.04 ± 1.05	16	50	62.28 ± 3.05

2.2.3 Anti-tyrosinase activity

The anti-tyrosinase activity assay results are presented in Table 5. All compounds were compared against kojic acid. Compounds **10–12** inhibited tyrosinase activity to a certain extent, with inhibition of 14.9, 11.4, and 11.2 %, respectively. Compounds **1, 3–6, 9, 13, and 15** exhibited minimal anti-tyrosinase activity, whilst the other compounds did not present any anti-tyrosinase activity. Compound **10**, named 1,2,4-trichloro-8-hydroxy-6-methylxanthone, exhibited the best inhibitory activity of 14.9%, versus 22% for 1,2,4-trichloro-6,8-dihydroxyxanthone [5]. The inhibitory activities of these two analogs were comparable in view of their different concentrations, indicating that tri-chlorine-substituted xanthenes were useful for their anti-tyrosinase activity. The elucidated structure–anti-tyrosinase activity relationship of these compounds will be beneficial for structural modification.

Table 5. Antit-yrosinase activities of compounds **1-16**

Compd	Conc (μM)	Inhibition (%)	Compd	Conc (μM)	Inhibition (%)
kojic acid	35	51.45 ± 0.15	9	100	5.66 ± 0.78
1	50	8.53 ± 3.85	10	50	14.87 ± 0.55
2	50	-6.55 ± 2.51	11	50	11.40 ± 1.09
3	50	9.09 ± 0.87	12	50	11.17 ± 0.33
4	50	9.01 ± 0.33	13	50	9.71 ± 0.87
5	100	7.68 ± 1.82	14	95	0.046 ± 1.43
6	100	10.99 ± 4.68	15	100	9.15 ± 1.30
7	50	-1.70 ± 1.09	16	50	-6.09 ± 0.98
8	50	-2.16 ± 0.87			

2.2.4 Anti-pancreatic lipase activity

The anti-pancreatic lipase activity assay results are presented in Table 6. All compounds were compared with orlistat. Compound **14** inhibited pancreatic lipase activity by >35% whilst compounds **1–2, 4, 10, 12, and 16** also exhibited minimal anti-pancreatic lipase activity. However, the other compounds were inactive.

Table 6. Anti-pancreatic lipase activities of compounds **1-16**

Compd	Conc (μM)	Inhibition (%)	Compd	Conc (μM)	Inhibition (%)
Orlistat	0.005	76.84 ± 0.49	9	100	-13.30 ± 2.68
1	50	13.40 ± 1.26	10	50	15.87 ± 2.91
2	50	16.59 ± 0.44	11	50	1.02 ± 7.03
3	50	0.81 ± 2.09	12	50	15.83 ± 2.47

4	50	9.83 ± 0.97	13	50	3.11 ± 3.40
5	100	-5.29 ± 0.23	14	95	36.83 ± 1.14
6	100	-19.02 ± 0.17	15	100	-13.34 ± 0.91
7	50	-9.24 ± 0.19	16	50	12.95 ± 3.54
8	50	-0.34 ± 1.48			

2.2.5 Antifungal activity

The antifungal activity assay results are presented in Table 7. Amphotericin B was used as a positive control. Amphotericin B completely inhibited *Candida albicans* whilst compound **16** presented 79.8% inhibition. It exhibited moderate inhibitory activity against *Candida albicans*.

Table 7. Inhibitory activity of compound **16** against *Candida albicans*

Compd	Conc (µg/ml)	Inhibition (%)
amphotericin B	0.25	100.15 ± 0.21
16	52	79.75 ± 2.23

3. Experimental

3.1 Chemistry

The chemical reagents purchased (Aladdin) were of the highest commercially available purity and were used directly. ¹H and ¹³C NMR spectra were determined in acetone-d₆ at 500 MHz for ¹H and 125 MHz for ¹³C. IR spectra were recorded with KBr pellets. High resolution mass (HRMS) data were recorded via a positive or negative ion electron impact mass spectrometry using a time-of-flight analyzer.

3.2 General procedure for preparation of substituted 1-hydroxy-3-methylxanthenes

A mixture of phosphorus pentoxide (0.36 g, 2.5 mmol) and methanesulfonic acid (10 mL) was heated at 110 °C until a clear solution was obtained. The temperature was then lowered to 90 °C and a mixture of 3,5-dihydroxytoluene (0.13 g, 1.0 mmol) and substituted salicylic acid (1.0 mmol) was added. Heating was then continued for several hours. The reaction progress was monitored by thin-layer chromatography (TLC) until the reaction was completed balanced, then the reaction mixture was poured into iced-water. The crude product was collected by filtration or extracted with ethyl acetate, washed with water, dried, and purified by medium pressure preparative chromatography with ethyl acetate/petroleum ether to afford the target xanthone.

5-Fluoro-1-hydroxy-3-methyl-9H-xanthen-9-one (**1**): yellow solid; yield 51%; mp: 183–184 °C; IR (KBr) ν_{\max} 720, 789, 843, 883, 1090, 1291, 1500, 1609, 1648, 2848, 2922, 3072, 3453 cm⁻¹; ¹H NMR (500 MHz, Acetone-d₆) δ 2.46 (s, 3H, -CH₃), 6.70 (s, 1H, H-2), 6.95 (s, 1H, H-4), 7.47 (td, 1H, $J = 4.5, 8.1$ Hz, H-7), 7.75 (t, 1H, $J = 9.2$ Hz, H-6), 8.02 (d, 1H, $J = 8.1$ Hz, H-8), 12.41 (s, 1H, 1-OH); ¹³C NMR (125 MHz, Acetone-d₆) δ 22.4, 108.4, 112.5, 121.7 (C-8, C-8a), 122.1, 122.2, 123.3, 124.8 and 124.8 (C-7, ³J_{CF} = 6.8 Hz), 150.9, 152.6, 156.6, 162.5, 181.8; HRMS(ESI) m/z calcd for C₁₄H₈FO₃ [M - H]⁻ 243.0463, found 243.0466.

6-Fluoro-1-hydroxy-3-methyl-9H-xanthen-9-one (**2**): yellow solid; yield 56%; mp: 150–152 °C; IR (KBr) ν_{\max} 666, 770, 787, 827, 844, 954, 1101, 1155, 1261, 1449, 1608, 1656, 2838, 2958, 3078, 3425 cm⁻¹; ¹H NMR (500 MHz, Acetone-d₆) δ 2.44 (s, 3H, -CH₃), 6.66 (s, 1H, H-2), 6.85 (s, 1H, H-4), 7.30 (td, 1H, $J = 2.3, 8.5$ Hz, H-7), 7.38 (dd, 1H, $J = 2.3, 9.7$ Hz, H-5), 8.29 (dd, 1H, $J = 6.5, 8.5$ Hz, H-8), 12.46 (s, 1H, 1-OH); ¹³C NMR (125 MHz, Acetone-d₆) δ 22.4, 105.3, 105.5, 107.2, 108.2, 112.3, 113.6 and 113.8 (C-7, ²J_{CF} = 23.3 Hz), 129.3, 129.4, 150.4, 157.2, 162.5,

166.7 and 168.8 (C-6, $^1J_{CF} = 252.8$ Hz), 181.6; HRMS(ESI) m/z calcd for $C_{14}H_8FO_3$ [M - H]⁻ 243.0463, found 243.0461.

7-Fluoro-1-hydroxy-3-methyl-9*H*-xanthen-9-one (**3**): yellow solid; yield 58%; mp: 160–161 °C; IR (KBr) ν_{max} 547, 573, 782, 820, 1215, 1279, 1366, 1477, 1493, 1619, 1652, 2827, 2971, 3085, 3453 cm^{-1} ; 1H NMR (500 MHz, Acetone- d_6) δ 2.43 (s, 3H, -CH₃), 6.64 (s, 1H, H-2), 6.84 (s, 1H, H-4), 7.65 (dd, 1H, $J = 4.4, 9.2$ Hz, H-5), 7.69 (m, 1H, H-6), 7.81 (dd, 1H, $J = 3.1, 8.2$ Hz, H-8), 12.34 (s, 1H, 1-OH); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.4, 108.2, 110.7, 110.9, 112.0, 121.3 and 121.3 (C-5, $^3J_{CF} = 8.1$ Hz), 122.1, 124.5, 124.7, 150.7, 157.0 and 158.6 (C-7, $^1J_{CF} = 196.5$ Hz), 160.6, 162.3, 181.7; HRMS(ESI) m/z calcd for $C_{14}H_8FO_3$ [M - H]⁻ 243.0463, found 243.0464.

1,2-Difluoro-8-hydroxy-6-methyl-9*H*-xanthen-9-one (**4**): light yellow solid; yield 52%; mp: 205–207 °C; IR (KBr) ν_{max} 796, 836, 893, 1201, 1292, 1477, 1510, 1615, 1651, 3060, 3430 cm^{-1} ; 1H NMR (500 MHz, Acetone- d_6) δ 2.45 (s, 3H, -CH₃), 6.68 (s, 1H, H-7), 6.88 (s, 1H, H-5), 7.66 (dd, 1H, $J = 6.4, 10.8$ Hz, H-4), 8.05 (t, 1H, $J = 9.6$ Hz, H-3), 12.28 (s, 1H, 8-OH); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.4, 107.0, 108.1, 108.3, 112.3, 112.4, 113.5, 113.7, 147.4 and 149.4 (C-1, $^1J_{CF} = 245.5$ Hz), 149.4 and 150.8 (C-2, $^1J_{CF} = 173.4$ Hz), 153.9, 157.2, 162.3, 181.0; HRMS(ESI) m/z calcd for $C_{14}H_7F_2O_3$ [M - H]⁻ 261.0369, found 261.0367.

7-(2,4-Difluorophenyl)-1-hydroxy-3-methyl-9*H*-xanthen-9-one (**5**): yellow solid; yield 60%; mp: 210–212 °C; IR (KBr) ν_{max} 805, 829, 1144, 1207, 1255, 1279, 1480, 1611, 1656, 2974, 3058, 3080, 3431 cm^{-1} ; 1H NMR (500 MHz, Acetone- d_6) δ 2.46 (s, 3H, -CH₃), 6.68 (s, 1H, H-2), 6.92 (s, 1H, H-4), 7.24 (m, 2H, H-3', H-5'), 7.72 (m, 2H, H-5, H-6'), 8.07 (d, 1H, $J = 8.7$ Hz, H-6), 8.35 (s, 1H, H-8), 12.51 (s, 1H, 1-OH); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.5, 105.1, 105.3 and 105.5 (C-3', $^2J_{CF} = 26.5$ Hz), 108.4, 112.1, 112.9 and 113.1 (C-5', $^2J_{CF} = 21.5$ Hz), 113.1, 119.4, 121.3, 126.3, 131.8, 132.9 and 132.9 (C-7, $^3J_{CF} = 4.4$ Hz), 133.0, 137.3 and 137.3 (C-6', $^3J_{CF} = 2.9$ Hz), 150.6, 156.5, 157.1, 162.5, 164.5, 182.3; HRMS(ESI) m/z calcd for $C_{20}H_{11}F_2O_3$ [M - H]⁻ 337.0682, found 337.0685.

1-Hydroxy-3-methyl-6-(trifluoromethyl)-9*H*-xanthen-9-one (**6**): yellow solid; yield 62%; mp: 180–182 °C; IR (KBr) ν_{max} 799, 903, 928, 994, 1065, 1205, 1317, 1357, 1445, 1496, 1566, 1615, 1651, 2858, 2931, 3079, 3438 cm^{-1} ; 1H NMR (500 MHz, Acetone- d_6) δ 2.46 (s, 3H, CH₃-), 6.70 (s, 1H, H-2), 6.91 (s, 1H, H-4), 7.78 (d, 1H, $J = 8.3$ Hz, H-7), 7.94 (s, 1H, H-5), 8.42 (d, 1H, $J = 8.3$ Hz, H-8), 12.29 (s, 1H, HO-1); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.5, 107.8, 108.4, 108.5, 112.4 (C-5, C-8a), 116.6 (q, $^3J_{CF} = 4.1$ Hz, C-7), 121.2 (q, $^4J_{CF} = 3.4$ Hz, C-8), 123.9, 128.1, 151.2, 156.6, 157.1, 162.5, 181.7; HRMS(ESI) m/z calcd for $C_{15}H_8F_3O_3$ [M - H]⁻ 293.0431, found 293.0430.

5-Chloro-1-hydroxy-3-methyl-9*H*-xanthen-9-one (**7**): yellow solid; yield 71%; mp: 208–209 °C; IR (KBr) ν_{max} 724, 784, 805, 843, 945, 1083, 1213, 1284, 1484, 1602, 1655, 2839, 2920, 3069, 3433 cm^{-1} ; 1H NMR (500 MHz, Acetone- d_6) δ 2.47 (s, 3H, -CH₃), 6.70 (s, 1H, H-2), 6.96 (s, 1H, H-4), 7.48 (t, 1H, $J = 8.0$ Hz, H-7), 7.99 (dd, 1H, $J = 0.9, 8.0$ Hz, H-6), 8.18 (dd, 1H, $J = 0.9, 8.0$ Hz, H-8), 12.37 (s, 1H, 1-OH); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.0, 107.3, 108.5, 112.5, 119.0, 122.8, 125.3 (C-7, C-8a), 136.6, 150.9, 152.5, 156.6, 162.5, 182.0; HRMS(ESI) m/z calcd for $C_{14}H_8ClO_3$ [M - H]⁻ 259.0167, found 259.0165.

6-Chloro-1-hydroxy-3-methyl-9*H*-xanthen-9-one (**8**): orange solid; yield 73%; mp: 165–167 °C; IR (KBr) ν_{max} 573, 665, 724, 795, 861, 926, 1078, 1206, 1280, 1368, 1435, 1600, 1652, 2853, 2919, 3071, 3440 cm^{-1} ; 1H NMR (500 MHz, Acetone- d_6) δ 2.44 (s, 3H, -CH₃), 6.66 (s, 1H, H-2), 6.86 (s, 1H, H-4), 7.50 (dd, 1H, $J = 1.9, 8.6$ Hz, H-7), 7.66 (d, 1H, $J = 1.9$ Hz, H-5), 8.21 (d, 1H, J

= 8.6 Hz, H-8), 12.40 (s, 1H, 1-OH); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.4, 107.5, 108.3, 112.3, 118.7, 120.1, 125.8, 128.1, 141.9, 150.7, 156.9, 157.3, 162.5, 181.8; HRMS(ESI) m/z calcd for $\text{C}_{14}\text{H}_8\text{ClO}_3$ $[\text{M} - \text{H}]^-$ 259.0167, found 259.0168.

7-Chloro-1-hydroxy-3-methyl-9*H*-xanthen-9-one (**9**): yellow solid; yield 76%; mp: 193–194 °C; IR (KBr) ν_{max} 536, 721, 813, 1081, 1207, 1279, 1367, 1468, 1623, 1650, 2850, 2925, 3064, 3433 cm^{-1} ; ^1H NMR (500 MHz, Acetone- d_6) δ 2.45 (s, 3H, CH_3 -), 6.67 (s, 1H, H-2), 6.89 (s, 1H, H-4), 7.65 (d, 1H, $J = 9.0$ Hz, H-5), 7.88 (dd, 1H, $J = 2.5, 9.0$ Hz, H-6), 8.13 (d, 1H, $J = 2.5$ Hz, H-8), 12.32 (s, 1H, HO-1); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.5, 107.4, 108.4, 112.2, 121.2, 122.4, 125.4, 130.1, 136.6, 150.9, 155.6, 157.0, 162.4, 181.4; HRMS(ESI) m/z calcd for $\text{C}_{14}\text{H}_{10}\text{ClO}_3$ $[\text{M} + \text{H}]^+$ 261.0313, found 261.0311.

1,2,4-Trichloro-8-hydroxy-6-methyl-9*H*-xanthen-9-one (**10**): yellow solid; yield 66%; mp: 254–256 °C; IR (KBr) ν_{max} 739, 836, 1004, 1091, 1207, 1254, 1444, 1625, 1651, 2841, 2923, 3062, 3437 cm^{-1} ; ^1H NMR (500 MHz, Acetone- d_6) δ 2.41 (s, 3H, $-\text{CH}_3$), 6.72 (s, 1H, H-7), 6.95 (s, 1H, H-5), 8.44 (s, 1H, H-3), 12.19 (s, 1H, 8-OH); ^{13}C NMR (125 MHz, Acetone- d_6) δ 21.9, 96.6, 99.8, 109.2, 112.1, 135.2 (C-1, C-9a), 150.0 (C-2, C-3), 164.7, 168.5, 173.7, 177.6, 195.0; HRMS(ESI) m/z calcd for $\text{C}_{14}\text{H}_7\text{Cl}_3\text{NaO}_3$ $[\text{M} + \text{Na}]^+$ 350.9353, found 350.9349.

5,7-Dibromo-1-hydroxy-3-methyl-9*H*-xanthen-9-one (**11**): yellow solid; yield 53%; mp: 232–234 °C; IR (KBr) ν_{max} 534, 725, 803, 831, 1078, 1206, 1260, 1354, 1467, 1590, 1626, 1647, 2846, 2918, 3066, 3435 cm^{-1} ; ^1H NMR (500 MHz, Acetone- d_6) δ 2.42 (s, 3H, $-\text{CH}_3$), 6.73 (s, 1H, H-2), 6.99 (s, 1H, H-4), 8.19 (d, 1H, $J = 2.4$ Hz, H-8), 8.43 (d, 1H, $J = 2.4$ Hz, H-6), 12.04 (s, 1H, 1-OH); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.0, 106.1, 107.9, 111.8, 112.5, 116.4, 122.6, 127.1, 140.5, 150.3, 151.4, 157.3, 160.5, 179.5; HRMS(ESI) m/z calcd for $\text{C}_{14}\text{H}_7\text{Br}_2\text{O}_3$ $[\text{M} - \text{H}]^-$ 380.8767, found 380.8771.

1-Hydroxy-3-methyl-9*H*-xanthen-9-one (**12**): yellow solid; yield 55%; mp: 127–130 °C; IR (KBr) ν_{max} 670, 760, 824, 924, 1080, 1205, 1290, 1377, 1482, 1611, 1656, 2852, 2922, 3048, 3428 cm^{-1} ; ^1H NMR (500 MHz, Acetone- d_6) δ 2.42 (s, 3H, $-\text{CH}_3$), 6.61 (d, 1H, $J = 0.5$ Hz, H-2), 6.81 (d, 1H, $J = 0.5$ Hz, H-4), 7.47 (t, 1H, $J = 8.0$ Hz, H-7), 7.54 (d, 1H, $J = 8.0$ Hz, H-5), 7.86 (m, 1H, H-6), 8.20 (dd, 1H, $J = 1.7, 8.0$ Hz, H-8), 12.54 (s, 1H, 1-OH); ^{13}C NMR (125 MHz, Acetone- d_6) δ 21.6, 106.6, 107.4, 111.0, 117.9, 120.4, 124.3, 125.5, 135.9, 149.4, 156.1, 156.2, 161.7, 181.6; HRMS(ESI) m/z calcd for $\text{C}_{14}\text{H}_{11}\text{O}_3$ $[\text{M} + \text{H}]^+$ 227.0703, found 227.0769.

1-Hydroxy-5-methoxy-3-methyl-9*H*-xanthen-9-one (**13**): yellowish solid; yield 64%; mp: 245–248 °C; IR (KBr) ν_{max} 523, 731, 810, 890, 970, 1088, 1166, 1274, 1364, 1492, 1609, 1648, 3013, 3428 cm^{-1} ; ^1H NMR (500 MHz, Acetone- d_6) δ 2.46 (s, 3H, $-\text{CH}_3$), 3.52 (s, 3H, $-\text{OCH}_3$), 6.71 (s, 1H, H-2), 7.05 (s, 1H, H-4), 7.55 (t, 1H, $J = 8.0$ Hz, H-7), 7.89 (dd, 1H, $J = 1.4, 8.0$ Hz, H-6), 8.20 (dd, 1H, $J = 1.4, 8.0$ Hz, H-8), 12.37 (s, 1H, 1-OH); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.4, 38.7, 107.5, 108.6, 112.5, 122.5, 123.2, 124.8, 125.1, 130.8, 138.6, 150.9, 156.5, 162.5, 181.9; HRMS(ESI) m/z calcd for $\text{C}_{15}\text{H}_{11}\text{O}_4$ $[\text{M} - \text{H}]^-$ 255.0663, found 255.0664.

1-Hydroxy-7-methoxy-3-methyl-9*H*-xanthen-9-one (**14**): yellow solid; yield 67%; mp: 172–174 °C; IR (KBr) ν_{max} 538, 849, 977, 1176, 1212, 1368, 1475, 1613, 1650, 2854, 2920, 3063, 3436 cm^{-1} ; ^1H NMR (500 MHz, Acetone- d_6) δ 2.45 (s, 3H, CH_3 -), 3.40 (s, 3H, $-\text{OCH}_3$), 6.68 (s, 1H, H-2), 6.90 (s, 1H, H-4), 7.72 (d, 1H, $J = 9.1$ Hz, H-5); 7.84 (dd, 1H, $J = 2.9, 9.1$ Hz, H-6), 8.12 (d, 1H, $J = 9.1$ Hz, H-8), 12.34 (s, 1H, HO-1); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.4, 37.7, 108.4, 112.2, 119.2, 121.0, 122.0, 130.9, 131.2, 146.4, 150.9, 155.3, 157.0, 162.4, 181.7; HRMS(ESI) m/z calcd for $\text{C}_{15}\text{H}_{11}\text{O}_4$ $[\text{M} - \text{H}]^-$ 255.0663, found 255.0659.

1,8-Dihydroxy-3-methyl-9*H*-xanthen-9-one (**15**): yellow solid; yield 56%; mp: 201–203 °C; IR (KBr) ν_{\max} 819, 917, 1061, 1208, 1231, 1289, 1482, 1602, 1631, 1661, 2852, 2920, 3022, 3431 cm^{-1} ; ^1H NMR (500 MHz, Acetone- d_6) δ 2.45 (s, 3H, CH_3 -), 6.67 (s, 1H, H-2), 6.79 (d, 1H, J = 8.4 Hz, H-7), 6.86 (s, 1H, H-4), 6.99 (d, 1H, J = 8.4 Hz, H-5), 7.74 (t, 1H, J = 8.4 Hz, H-6), 11.63 (s, 1H, HO-8), 11.77 (s, 1H, HO-1); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.4, 108.0 (C-2, C-4), 108.5, 111.4, 112.2, 112.3, 138.7, 151.4, 157.1, 157.2, 161.9, 162.2, 186.7; MS-ESI, m/z 241 [M - H] $^-$. HRMS(ESI) m/z calcd for $\text{C}_{14}\text{H}_9\text{O}_4$ [M - H] $^-$ 241.0506, found 241.0508.

1,5,6-Trihydroxy-3-methyl-9*H*-xanthen-9-one (**16**): brown solid; yield 33%; mp: 309–312 °C; IR (KBr) ν_{\max} 460, 788, 886, 1055, 1162, 1210, 1282, 1464, 1586, 1612, 1656, 2853, 2924, 3076, 3181, 3401, 3514 cm^{-1} ; ^1H NMR (500 MHz, Acetone- d_6) δ 2.41 (s, 3H, $-\text{CH}_3$), 6.59 (s, 1H, H-2), 6.80 (s, 1H, H-4), 7.00 (d, 1H, J = 8.8 Hz, H-7), 7.65 (d, 1H, J = 8.8 Hz, H-8), 8.73 (s, 1H, 5-OH), 9.25 (s, 1H, 6-OH), 12.83 (s, 1H, 1-OH); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.3, 106.8, 108.0, 111.6, 111.7, 113.9, 114.9, 117.6, 147.1, 149.2, 152.4, 157.0, 162.7, 182.1; HRMS(ESI) m/z calcd for $\text{C}_{14}\text{H}_9\text{O}_5$ [M - H] $^-$ 257.0455, found 257.0454.

1,6-Dihydroxy-5-methoxy-3-methyl-9*H*-xanthen-9-one (**17**): brown solid; yield 41%; mp: 270–273 °C; IR (KBr) ν_{\max} 524, 694, 831, 889, 974, 1051, 1177, 1224, 1284, 1365, 1462, 1504, 1579, 1609, 1654, 1728, 2852, 2922, 2957, 3020, 3260 cm^{-1} ; ^1H NMR (500 MHz, Acetone- d_6) δ 2.44 (s, 3H, 3- CH_3), 3.54 (s, 3H, 5- OCH_3), 6.65 (d, 1H, J = 0.6 Hz, H-2), 6.92 (d, 1H, J = 0.6 Hz, H-4), 7.17 (d, 1H, J = 8.0 Hz, H-7), 8.02 (d, 1H, J = 8.0 Hz, H-8), 10.61 (s, 1H, 6-OH), 12.58 (s, 1H, 2-OH); ^{13}C NMR (125 MHz, Acetone- d_6) δ 22.3, 68.3, 106.9, 108.3, 112.4, 114.8, 115.0, 125.5, 129.6, 132.0, 150.0, 156.6, 157.7, 162.5, 181.2; HRMS(ESI) m/z calcd for $\text{C}_{15}\text{H}_{11}\text{O}_5$ [M - H] $^-$ 271.0612, found 271.0615.

3.3 Bioassay

3.3.1 Cytotoxicity assay

The human cell lines SMMC-7721, HepG-2, Huh-7, SK-HEP-1, MHCC97H, PLC/PRF/5, L02, A-549, NCI-H460, NCI-H520, SPC-A-1, A549/Taxol, BEAS-2B, HL-60, MCF-7, MDA-MB-231, SW480 and HeLa were used in the cytotoxic assay. These cell lines were obtained from ATCC (Manassas, VA, USA). Cells were cultured in RPMI-1640 or DMEM medium (Biological industries, Kibbutz Beit-Haemek, Israel), supplemented with 10% fetal bovine serum (Biological Industries) at 37 °C in a humidified atmosphere with 5% CO_2 . The cytotoxicity assay was evaluated by MTS (Promega, Madison, WI, USA) assay [6]. Briefly, cells were seeded into each well of a 96-well cell culture plate. After 12 h of incubation at 37 °C, the test compound (40 μM) was added. After incubation for 48 h, cells were subjected to the MTS assay. Compounds with a growth inhibition of 50% were further evaluated at concentrations of 0.064, 0.32, 1.6, 8, and 40 μM in triplicate. Cisplatin and Taxol (Sigma, St. Louis, MO, USA) served as positive controls. The IC_{50} value of each compound was calculated using the method of Reed and Muench [7]. The results were expressed as average \pm standard deviation.

3.3.2 Mushroom tyrosinase in vitro inhibition

The sample or kojic acid standard (final concentration: 35 μM) was mixed with L-DOPA (final concentration: 1.25 mM) in a 96-well microplate. Each test particle was assayed in triplicate. The reaction was initiated by adding tyrosinase (final concentration: 25 U/mL). The plate was incubated at room temperature on a shaker for 5 min. The plates were read at 490 nm. The results were expressed as average \pm standard deviation. The effect of tyrosinase inhibition was calculated by using the following equation:

Tyrosinase (%) = (1 - mean OD of sample/mean OD of untreated control) × 100%

3.3.3 *In vitro* antioxidant capacity

Sample or the trolox standard (final concentration, 25 μM) was added to 96-well microplates. Each test particle was assayed in triplicate. The reaction was initiated by adding DPPH solution (final concentration, 50 μM) at 30 °C for 1 h. The plates were read at 515 nm. The results were expressed as average ± standard deviation. The antioxidant effect was calculated by using following equation:

Antioxidant (%) = (1 - mean OD of sample/mean OD of untreated control) × 100%

3.3.4 Measurement of inhibitory activity against lipase

Porcine pancreatic lipase (PPL), Dulbecco's phosphate-buffered saline (D-PBS), and anhydrous calcium chloride were purchased from Aladdin Reagent (Shanghai, China), Hyclone (Logan, Utah, USA), and Chengdu Kelon Chemical Reagent Factory (Chengdu, China), respectively. *p*-Nitrophenyl butyrate (*p*-NPB), Tris, and orlistat were purchased from Sigma-Aldrich. The test compounds were thoroughly mixed with the PPL solution and then added to a 96-well microplate. Each test compound was assayed in triplicate. The test mixture was kept at 37 °C for 15 min then *p*-NPB was added to the well and mixed evenly. This new mixture was kept at 37 °C for 15 min. The plates were read at 400 nm with 630 nm as the reference wavelength. At the same time, the blank control well and the orlistat positive control well were set [8-10]. The results were expressed as the average ± standard deviation. The inhibitory activity was calculated using the following equation:

PPL activity inhibition (%) = (1 - mean OD of sample/OD value of control well) × 100%

3.3.5 Antifungal activity

Candida albicans ATCC 10231 was purchased from Microbiologics (Minnesota, USA). Amphotericin B and DMSO were purchased from Sigma-Aldrich, and agar powder was purchased from Aladdin Reagent (Shanghai, China). A dimethyl sulfoxide (DMSO) solution containing the sample (final concentration, 200 μM) was added to a 96-well microplate. Subsequently, a dimethyl sulfoxide (DMSO) solution containing *Candida albicans* (final concentration, 1 × 10⁵ CFU/mL) was added to each well. Each test compound was assayed in triplicate. This mixture was incubated at 37 °C for 24 h. The plates were read at 625 nm. At the same time, the blank control well and the positive control well containing amphotericin B were set [11-12]. The results were expressed as the average ± standard deviation. The inhibitory activity was calculated by using the following equation:

Antifungal activity inhibition (%) = (1 - mean OD of sample/OD value of control well) × 100%

Acknowledgments

The authors gratefully thank the Leading Project of Fujian Provincial Department of Science and Technology (Grant number 2018Y0072) for the support of this program.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Mahabusarakam, W.; Rattanaburi, S.; Phongpaichit, S.; Kanjana-Opas, A. *Phytochem Lett.* **2008**,

- 1, 211–214. doi: 10.1016/j.phytol.2008.09.012
2. Reyes-chilpa, R.; Jimenez-estrada, M.; Estrada-muñiz E. *J. Chem. Ecol.* **1997**, *23*, 1901–1911. doi: 10.1023/B:JOEC.0000006459.88330.61
3. Jung, H. A.; Su, B. N.; Keller, W. J.; Mehta, W. G.; Kinghorn, A. D. *J. Agric. Food Chem.* **2006**, *54*, 2077–2082. doi: 10.1021/jf052649z
4. Zhou, B. D.; Zeng, L. L.; Tong, Y. G.; Fang, J. Y.; Ruan, Z. P.; Zeng, X. Y.; Fang, Y. Y.; Xu, G. F.; Hu, D. B. *J. Asian Nat. Prod. Res.* **2018**, *20*, 467–476. doi: 10.1080/10286020.2018.1454437
5. Zhou, B. D.; Wang, X.; Weng, Z. M.; Huang, B. C.; Ma, Z. T.; Yu, B.; Ruan, L. Q.; Hu, D. B. *J. Chin. Pharm. Sci.* **2019**, *28*, 247–256. doi: 10.5246/jcps.2019.04.025
6. Cory, A. H.; Owen, T. C.; Barltrop, J. A.; Cory, J. G. *Cancer Commun.* **1991**, *3*, 207–212.
7. Reed, L. J.; Muench, H. *Am. J. Hyg.* **1938**, *27*, 493–497.
8. Seyedan, A.; Alshawsh, M. A.; Alshagga, M. A.; Koosha, S.; Mohamed, Z. *Evid-based Compl. Alt.* **2015**, *2015*, 1–13. doi: 10.1155/2015/973143
9. Buchholz, T.; Melzig, M. F. *Planta Med.* **2015**, *81*, 771–783. doi: 10.1055/s-0035-1546173
10. Kim, J. H.; Kim, H. J.; Park, H. W.; Youn, S. H.; Choi, D. Y.; Shin, C. S. *FEMS Microbiol Lett.* **2007**, *276*, 93–98. doi: 10.1111/j.1574-6968.2007.00917.x
11. Pedras, M. S. C.; Abdoli, A.; *Bioorg. Med. Chem.* **2018**, *26*, 4461–4469. doi: 10.1016/j.bmc.2018.07.030
12. Łukowska-Chojnacka, E.; Mierzejewska, J.; Milner-Krawczyk, M.; Bondaryk, M.; Staniszewska, M. *Bioorg. Med. Chem.* **2016**, *24*, 6058–6065. doi: 10.1016/j.bmc.2016.09.066